Serum Level of CC-Chemokine Ligand 18 Is Increased in Patients with Non-Small-Cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas

CC-chemokine ligand 18 (CCL18) is mainly expressed by alternatively activated macrophages and DCs and plays an important role in lung fibrosis, arthritis and other diseases. Here CCL18 was measured in sera of 31 healthy volunteers and 170 patients with lung cancer and correlated these data with histology, tumor stage and clinical parameters. Mean CCL18 serum level of the patients with non-small-cell lung cancer was 150(857) ng/ml vs. 32(61) ng/ml in the healthy control group. Patient groups differ significantly according their histology (adenocarcinoma 143(528) ng/ml vs squamous cell carcinoma 187(857) ng/ml, p<0.02). In addition, we found a significant difference between patients with lower versus higher T-stage (p<0.003). Receiver operating characteristic (ROC) analyses revealed a cutoff point of 83 ng/ml (area under the curve (AUC): 0.968; p<0.0001) to discriminate between healthy controls and non-small-cell lung cancer patients. ROC analyses to discriminate between patients, who died because of cancer related death and those who died for other reasons did not lead to a valid AUC. To stratify the tumor patients, a criterion value plot was performed leading to a point of equal sensitivity and specificity (54%) of 162 ng/ml. Patients with a CCL18 serum level higher than 160 ng/ml had a mean survival time of 623 days. In contrast, those in patients with a baseline level between 83 ng/ml and 160 ng/ml the mean survival time was 984 days (p<0.005). Survival-analysis revealed in adenocarcinoma a mean survival of 1152 days in the group below 83 ng/ml. In the median group the mean survival time was 788 days and in the group with the highest levels the mean survival time was 388 days (p<0.001). In contrast, we found no correlation between the FEV1 and the CCL18 baseline level. In conclusion, in patients suffering from adenocarcinoma increased serum CCL18 levels predict a diminished survival time.

[1]  P. Bradding,et al.  Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer , 2010, BMC Cancer.

[2]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[3]  Jun Wang,et al.  Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma , 2011, Medical oncology.

[4]  M. Manns,et al.  Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. , 2005, Cancer research.

[5]  T. Biedermann,et al.  CCL18 Is Expressed in Atopic Dermatitis and Mediates Skin Homing of Human Memory T Cells , 2005, The Journal of Immunology.

[6]  Xin Chen,et al.  Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer. , 2004, Gastroenterology.

[7]  B. Wallaert,et al.  The chemokine CCL18 generates adaptive regulatory T cells from memory CD4+ T cells of healthy but not allergic subjects. , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[10]  J. Pollard,et al.  Role of infiltrated leucocytes in tumour growth and spread , 2004, British Journal of Cancer.

[11]  Boris Bleijlevens,et al.  Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. , 2004, Blood.

[12]  S. Jimenez,et al.  Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. , 2003, American journal of respiratory cell and molecular biology.

[13]  G. Sica,et al.  CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. , 2009, The Journal of thoracic and cardiovascular surgery.

[14]  Antje Prasse,et al.  A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. , 2006, American journal of respiratory and critical care medicine.

[15]  S. Fox,et al.  Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβ in primary invasive breast carcinomas , 2008, Breast Cancer Research and Treatment.

[16]  Q. Li,et al.  Evaluation of Proteomics-Identified CCL18 and CXCL1 as Circulating Tumor Markers for Differential Diagnosis between Ovarian Carcinomas and Benign Pelvic Masses , 2011, The International journal of biological markers.

[17]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[18]  T. Sasada,et al.  CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies , 2003, Cancer.

[19]  T. Meshel,et al.  Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. , 2008, Cytokine.

[20]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[21]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[23]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[24]  G. Lorusso,et al.  The tumor microenvironment and its contribution to tumor evolution toward metastasis , 2008, Histochemistry and Cell Biology.

[25]  G. Opdenakker,et al.  PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. , 2003, The American journal of pathology.

[26]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[27]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[28]  L. Edwards,et al.  Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. , 2011, American journal of respiratory and critical care medicine.

[29]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[30]  H. Pircher,et al.  Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. , 2009, Blood.

[31]  E. Brambilla,et al.  The evolving role of histology in the management of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Y. Sakaki,et al.  A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. , 1997, Journal of immunology.

[33]  T. Whiteside,et al.  Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer , 2005, British Journal of Cancer.

[34]  R. Govindan,et al.  Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  P. Allavena,et al.  Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation , 2009, Journal of leukocyte biology.

[36]  P. Allavena,et al.  Identification of Biologically Active Chemokine Isoforms from Ascitic Fluid and Elevated Levels of CCL18/Pulmonary and Activation-regulated Chemokine in Ovarian Carcinoma* , 2002, The Journal of Biological Chemistry.

[37]  M. Olschewski,et al.  Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[38]  D. Schadendorf,et al.  Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  E. Thiel,et al.  Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. , 2008, Human pathology.